Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
DMIIR0.116USD
0.0000.00%
終値 01/27, 16:00（ET）15分遅れの株価
0.00時価総額
--直近12ヶ月PER
詳細情報 Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 企業名
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030の企業情報
企業コードDMIIR
会社名Drugs Made In America Acquisition II Corp
上場日Sep 25, 2025
最高経営責任者「CEO」Stockwell (Lynn)
従業員数- -
証券種類Right
決算期末- -
本社所在地1 East Broward Boulevard
都市FT LAUDERDALE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号33301
電話番号19548703099
ウェブサイト
企業コードDMIIR
上場日Sep 25, 2025
最高経営責任者「CEO」Stockwell (Lynn)
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030の経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
株主統計
種類
株主統計
株主統計
比率
他の
100.00%
株主統計
株主統計
比率
他の
100.00%
種類
株主統計
比率
他の
100.00%
機関投資家保有株
会社から関連データがまだ開示されていません。
報告期間
機関投資家数
保有株式数
比率
変動額
データなし
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
データなし
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
